Looking for excipients offered by SPI Pharma? Find information on SPI Pharma's regulatory filings (DMFs), cGMP inspections, pricing availability, etc. on PharmaCompass.

PharmaCompass

SPI Pharma has been solving formulation challenges using superior functional materials.

Related CompaniesRelated Companies

About

For over 75 years, SPI Pharma has been supplying highly engineered products and innovative solutions to the pharmaceutical and nutritional industries to improve the formulation and delivery of drug products to meet patient needs. Owned by Associated British Foods, SPI Pharma has established itself as a global leader, serving over 55 countries in the manufacture and marketing of antacid actives, specialty excipients, drug delivery systems and taste-masking technology for solid oral and oral dispersible dosage forms.

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
Rockwood Office Park, 503 Carr Rd., Suite 210, Wilmington, DE 19809
Telephone
Telephone
+1 8007899755
Contact Info
Others

Events

Webinars & Exhibitions

A PHP Error was encountered

Severity: Warning

Message: Undefined variable $tile1

Filename: tabs/exhibitions.php

Line Number: 43

Backtrace:

File: /var/www/html/application/views/include/party/inc/tabs/exhibitions.php
Line: 43
Function: _error_handler

File: /var/www/html/application/models/CmnPec.php
Line: 1626
Function: view

File: /var/www/html/application/views/include/party/query.php
Line: 575
Function: create

File: /var/www/html/application/views/include/party/indexNew.php
Line: 86
Function: include

File: /var/www/html/application/views/commonNew.php
Line: 1369
Function: include

File: /var/www/html/application/controllers/PharmaServices.php
Line: 6874
Function: view

File: /var/www/html/index.php
Line: 224
Function: require_once

cphi-india-2024-91846.png

CPhI India 2024

Contact Supplier

Meeting

Digital content read-more

Explore the latest content creation from this company

CORPORATE CONTENT #SupplierSpotlight

    https://www.pharmacompass.com/pdf/party/content/spi-pharma-party-content-52666.pdf

    https://www.pharmacompass.com/pdf/party/content/spi-pharma-party-content-89304.pdf

    https://www.pharmacompass.com/pdf/party/content/spi-pharma-party-content-64912.pdf

    https://www.pharmacompass.com/pdf/party/content/spi-pharma-party-content-95271.pdf

    https://www.pharmacompass.com/pdf/party/content/spi-pharma-party-content-79696.pdf

    https://www.pharmacompass.com/pdf/party/content/spi-pharma-party-content-55001.pdf

    https://www.pharmacompass.com/pdf/party/content/spi-pharma-party-content-40033.pdf

    https://www.pharmacompass.com/pdf/party/content/spi-pharma-party-content-5272.pdf

    https://www.pharmacompass.com/pdf/party/content/spi-pharma-party-content-11176.pdf

    https://www.pharmacompass.com/pdf/party/content/spi-pharma-party-content-40487.pdf

    https://www.pharmacompass.com/pdf/party/content/spi-pharma-party-content-43471.pdf

    https://www.pharmacompass.com/pdf/party/content/spi-pharma-party-content-10306.pdf

    https://www.pharmacompass.com/pdf/party/content/spi-pharma-party-content-42405.pdf

    https://www.pharmacompass.com/pdf/party/content/spi-pharma-party-content-94551.pdf

    https://www.pharmacompass.com/pdf/party/content/spi-pharma-party-content-21162.pdf

    https://www.pharmacompass.com/pdf/party/content/spi-pharma-party-content-80910.pdf

    https://www.pharmacompass.com/pdf/party/content/spi-pharma-party-content-69455.pdf

    https://www.pharmacompass.com/pdf/party/content/spi-pharma-party-content-98892.pdf

    https://www.pharmacompass.com/pdf/party/content/spi-pharma-party-content-40506.pdf

    https://www.pharmacompass.com/pdf/party/content/spi-pharma-party-content-48876.pdf

    https://www.pharmacompass.com/pdf/party/content/spi-pharma-party-content-98715.pdf

    https://www.pharmacompass.com/pdf/party/content/spi-pharma-party-content-93650.pdf

    https://www.pharmacompass.com/pdf/party/content/spi-pharma-party-content-12752.pdf

    https://www.pharmacompass.com/pdf/party/content/spi-pharma-party-content-44384.pdf

    https://www.pharmacompass.com/pdf/party/content/spi-pharma-party-content-2274.pdf

DATA COMPILATION #PharmaFlow

read-more
read-more
Excipient Market Overview: Roquette, Seqens, Evonik make strategic moves; new guidelines deal with contamination
The pharmaceutical industry has long recognized the critical role excipients or inactive ingredients play in drug formulation and delivery. Excipients can comprise up to 90 percent of a medicine's total ingredients and serve crucial functions as binders, disintegrants, coatings, preservatives, colors, and flavorings. According to recent market research, the pharmaceutical excipients market was valued at US$ 9.27 billion in 2023. It is growing at a compound annual growth rate (CAGR) of 7.03 percent and is projected to reach US$ 18.48 billion by 2032. The main factors driving market growth is an increased demand for multifunctional excipients, coupled with the expanding use of generic medications. The development in the biologics sector and advancements in nanotechnology are also contributing significantly to market growth. Major excipient providers include BASF, Evonik, Merck KGaA owned MilliporeSigma, Gangwal Healthcare, Roquette Frères, DuPont, Croda International, Seqens, Boai NKY Pharmaceuticals, PMC Isochem, Minakem, Kewpie Corporation, Ashland Global, SPI Pharma, Pfanstiehl, Nanjing Well Pharmaceutical, ICE Pharma, Anhui Ribobay Pharmaceutical and Nippon Fine Chemical.  View Our Dashboard on Major Excipient Companies in 2024 (Free Excel Available) WHO, India’s CDSCO tighten regulations; new GMP guidelines implemented to curb contamination Last year, the World Health Organization (WHO) issued a health alert linking at least 300 child deaths in the Gambia, Uzbekistan, and Indonesia to the ingestion of contaminated cough syrups containing unacceptable levels of diethylene glycol (DEG) and ethylene glycol (EG). In response to the tragic events, the WHO released two draft appendices to its guideline on good manufacturing practices (GMPs) for excipients this year. Manufacturers are now required to use suitable risk assessment tools to identify and mitigate potential hazards.  Since India-made cough syrups had been linked to the deaths, India’s drug regulator — Central Drugs Standard Control Organization (CDSCO) — took steps to prevent contamination, and advised drugmakers to only use pharmaceutical-grade excipients from approved sources. Furthermore, the Indian Health Ministry proposed amendments to the Drugs and Cosmetics Rules, 1945 to include details of excipients on drug labels. While listing all excipients on every strip of medicine may be challenging, the ministry suggested mentioning those causing hypersensitivity on the label. Applicants now mandatorily need to submit evidence of stability and safety of excipients. These regulatory developments have significant implications for excipient manufacturers and pharmaceutical companies worldwide. Leading pharmaceutical excipient firms like Gangwal Healthcare, Sigachi Industries, and Nitika Pharmaceuticals are well-positioned to meet these heightened quality and safety standards, given their long-standing commitment to producing high-quality, compliant excipients.  View Our Dashboard on Major Excipient Companies in 2024 (Free Excel Available)   Roquette buys IFF’s pharma unit for US$ 2.85 bn; Evonik opens new spray-drying facility in Darmstadt In a significant industry move, France-based Roquette entered into an agreement to acquire IFF's pharma solutions business in a deal valued at US$ 2.85 billion. This acquisition is set to rebalance family-owned Roquette’s portfolio around health and nutrition. The deal is expected to accelerate Roquette’s growth and significantly strengthen its presence in the excipients market. Evonik has opened a new facility for drying aqueous dispersions of its Eudragit polymers at its site in Darmstadt, Germany. The facility will help Evonik meet increasing demand from drugmakers for its oral drug delivery solutions. The plant uses green energy solutions. The company has also partnered University of Mainz to commercialize a new class of polyethylene glycols (PEG) lipids for nucleic acid delivery. Evonik’s Health Care business has been growing its nucleic acid drug and vaccine delivery portfolio.  Germany’s Johannes Gutenberg University of Mainz was the first to develop randomized polyethylene glycols (rPEGs). This collaboration aims to expand Evonik’s toolbox of technologies for nucleic acid-based medicines, offering an improved immunogenicity profile for lipid nanoparticle carriers used in mRNA vaccines and therapeutics. Asahi Kasei made significant strides in addressing a pressing industry concern that emerged in 2018 when potentially carcinogenic nitrosamine impurities were detected in several pharmaceuticals. Guided by regional authorities, such as the European Medicines Agency and the US Food and Drug Administration, the pharmaceutical industry has been carrying out extensive assessments and research to identify the cause of these impurities. In response to this challenge, Asahi Kasei developed its Ceolus microcrystalline cellulose with extremely low nitrite levels. The Japanese company achieved nitrite concentrations of 0.1 micrograms per gram or less, which is equivalent to 0.1 parts per million (ppm). The company also started full commercial operation of its second manufacturing facility for Ceolus in Japan, enhancing supply capacity and stability. JRS Pharma and Gujarat Microwax opened a state-of-the-art cotton-based croscarmellose sodium plant in Mehsana, Gujarat (India). This facility aims to produce high-quality excipients that meet global standards, potentially reducing India's dependency on imports and boosting its presence in the global excipient market. The Indian excipient industry accounts for less than 1 percent of the global market share.  View Our Dashboard on Major Excipient Companies in 2024 (Free Excel Available)   Seqens to advance innovative polymer; biologics, personalized medicine create demand for specialized excipients Recent industry collaborations highlight the ongoing innovation in novel excipients. France’s Seqens, with over 20 years of polymer development experience, was chosen by Pleryon Therapeutics to advance its leading osteoarthritis candidate – an innovative GMP polymer. This collaboration leverages Seqens’ newly expanded and modernized cGMP plant in Aramon, France, demonstrating the industry’s commitment to investing in advanced manufacturing capabilities for novel excipients.  The rise of biologics and personalized medicine has created a demand for specialized excipients capable of stabilizing complex molecules and enabling targeted drug delivery. Roquette’s launch of Lycagel Flex, a hydroxypropyl pemix for nutraceutical and pharmaceutical softgel capsules, exemplifies this trend. Built on Roquette’s market-first Lycagel pea starch technology, this plant-based alternative to gelatin offers manufacturers the flexibility to customize formulations for a range of production and end-user needs. The innovative pea starch foundation also underscores the industry’s move towards sustainable bio-based excipients. The trend towards patient-centric drug development has also influenced excipient innovation. Excipients that can improve palatability, ease of swallowing, or enable novel dosage forms (such as orally disintegrating tablets) are in high demand. For example, IFF brought a super disintegrant Ac-Di-Sol, that supports faster disintegration and drug dissolution in oral disintegrating tablets, improving patient experience.  View Our Dashboard on Major Excipient Companies in 2024 (Free Excel Available)   Our view The heightened regulatory scrutiny on excipients due to product contamination incidents has created a high risk perception and uncertainty around the regulatory acceptance of novel excipients. That said, novel excipients are central to the development of new drug modalities and therapies. Going forward, sustainability will also become an increasingly important factor in excipient selection and development. As the industry innovates towards biologics, personalized therapies, and patient-centric formulations, the role of high-quality, multifunctional excipients will only grow more vital in ensuring drug stability, bioavailability, and patient compliance. Companies that can navigate the complex regulatory landscape, invest in R&D, and offer high-quality, multifunctional excipients will be well-positioned to succeed in this evolving market.   

Impressions: 1481

https://www.pharmacompass.com/radio-compass-blog/excipient-market-overview-roquette-seqens-evonik-make-strategic-moves-new-guidelines-deal-with-contamination

#PharmaFlow by PHARMACOMPASS
12 Sep 2024

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/spi-pharma-inc-and-inimmune-corp-partner-to-develop-and-commercialize-innovative-vaccine-adjuvant-systems-302198093.html

PR NEWSWIRE
17 Jul 2024

https://www.spipharma.com/en/insights-and-events/news-blog/embracing-patient-centric-formulations-for-a-healthier-tomorrow/

PRESS RELEASE
08 Jan 2024

https://www.spipharma.com/en/insights-and-events/news-blog/offering-broader-access-to-sustainable-and-scalable-pharma-grade-saponin-adjuvants/

PRESS RELEASE
13 Oct 2023

https://www.excipact.org/news-reader/spi-pharma-in-grand-haven-usa-receives-excipact-gmp-certification-as-pharmaceutical-excipient-supplier.html

EXCIPACT
10 Jul 2023

https://www.pharmacompass.com/pdf/news/spi-pharma-inc-announces-signing-of-regional-sole-distribution-agreement-for-actillets-mcc-microcrystalline-cellulose-pellets-tap-tartaric-acid-pellets-and-directly-compressible-ibuprofen-dc100-with-ingredientpharm-84886.pdf

PRESS RELEASE
09 Mar 2023

https://www.spipharma.com/en/news-and-events/events/cphi-frankfurt-2022/

PRESS RELEASE
01 Nov 2022

Excipients

Discover the DDS // excipients from this company

KEY EXCIPIENTS

read-more
read-more

TOP RANKED SUPPLIER FOR:

TOP RANKED SUPPLIER FOR:

Advantol 300
full-view
AHMC 0600
full-view
Advantol 300
full-view
Advantol 300
full-view
Advantol 300
full-view

Excipients by Ingredients

Discover their expertise by components

Mannitol

read-more
read-more

07

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSPI Pharma has been solving formulation challenges using superior functional materials.

Grade : Oral

SPI Pharma

Excipient Details : Mannogem Emerald is a compendial, powder mannitol dissolves quickly, delivering excellent palatability through a creamy texture and mild sweetness.

Pharmacopoeia Ref : NA

Technical Specs : 25 µm Powder Mannitol

arrow

08

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSPI Pharma has been solving formulation challenges using superior functional materials.

Grade : Oral

SPI Pharma

Excipient Details : Mannogem® Onyx is a compendial, powder mannitol has reduced sensitivity to lubricants, low friability, and high binding capacity.

Pharmacopoeia Ref : NA

Technical Specs : 50 µm Powder Mannitol

arrow

09

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSPI Pharma has been solving formulation challenges using superior functional materials.

Grade : Oral

click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Excipients By applications

Discover their expertise by claims

Inspections and registrations

Check the inspections & registration from this company

ABOUT THIS PAGE

Contact SPI Pharma and get a quotation

SPI Pharma is a supplier offers 4 products (APIs, Excipients or Intermediates).

Find a price of Magnesium Hydroxide bulk with DMF, CEP offered by SPI Pharma

Find a price of Aluminum bulk with CEP offered by SPI Pharma

Find a price of Magnesium Hydroxide bulk with CEP offered by SPI Pharma

Find a price of CALCIUM CARBONATE, MAG. HYDROXIDE GRAN bulk with DMF offered by SPI Pharma

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty